Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery
Biomolecules · 2025
DOI: 10.3390/biom15081173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Moritz Meyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Aust…. Hauptthemen laut MEDLINE: Weight Loss, Bariatric Surgery, Liver, Diazepam Binding Inhibitor. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The incidence and prevalence of obesity and related cardio-metabolic diseases are on the rise, posing a critical health care challenge to systems across the globe. Bariatric surgery is a therapeutic cornerstone for morbidly obese patients, besides novel medical treatments, partly by ameliorating metabolic inflammation, a hallmark of metabolic diseases. Acyl-CoA Binding Protein (ACBP), also known as diazepam-binding inhibitor (DBI), is a regulator of autophagy and metabolism, and has recently been shown to increase in individuals undergoing voluntary fasting and in patients with cancer cachexia-induced malnutrition. By analyzing a prospectively collected study with matched serum and liver samples from patients undergoing laparoscopic adjustable gastric banding at baseline and six months after surgery, we here demonstrate that ACBP serum levels significantly increase following bariatric surgery. Hepatic ACBP expression at baseline predicted weight loss six months after the procedure. The predictive value of ACBP warrants further study, as it could identify patients who benefit most from metabolic surgery in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria.
- Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Paul Gruber, Christina Plattner, Andreas Zollner, Herbert Tilg
Zitieren
APA
Meyer, M., Gruber, P., Plattner, C., Enrich, B., Zollner, A., Jukic, A., Effenberger, M., Grander, C., Tilg, H., & Grabherr, F. (2025). Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery. Biomolecules. https://doi.org/10.3390/biom15081173
Vancouver
Meyer M, Gruber P, Plattner C, Enrich B, Zollner A, Jukic A, et al. Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery. Biomolecules. 2025. doi:10.3390/biom15081173
BibTeX
@article{Meyer2025,
author = {Meyer, Moritz and Gruber, Paul and Plattner, Christina and Enrich, Barbara and Zollner, Andreas and Jukic, Almina and Effenberger, Maria and Grander, Christoph and Tilg, Herbert and Grabherr, Felix},
title = {Hepatic Expression of ACBP Is a Prognostic Marker for Weight Loss After Bariatric Surgery},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15081173}
}
EUVIMED